Bausch + Lomb Corporation is a global leader in eye health, offering a diverse range of products and services. Key strengths include a solid gross margin of 62.2%, indicating strong pricing power, and a healthy current ratio of 1.55, suggesting good liquidity. However, concerns arise from a negative net margin of -1.0% and low returns on equity and assets, which may signal profitability challenges. The high gross margin juxtaposed with low net profitability could indicate inefficiencies or high operating costs that need addressing.
Loading financial metrics...
Debt of $5.1B is 13.9x the company's cash position of $367.0M.
Operating margin expanded by 4.1pp, demonstrating strong operational leverage.
Both gross margin (+1.8pp) and operating margin (+4.1pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 61.5% indicates strong pricing power and competitive moat.
Operating cash flow surged 63.9% YoY, indicating strong cash generation capability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Based on 2026-Q2 (June 30, 2026)